# US 2024/0181077 A1 · An artificial protein-cage comprising encapsulated therein a guest cargo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0181077 A1
- Document ID: US20240181077A1
- Status: Published application
- Kind: A1
- Application number: 18/547,242
- Filed: 2022-02-24
- Published: 2024-06-06
- Earliest claimed: 2021-02-24
- Applicants: Uniwersytet Jagiellonski
- Inventors: Jonathan HEDDLE; Artur BIELA; Yusuke AZUMA; Antonina NASKALSKA; Kinga BORZECKA-SOLARZ; Jan ROZYCKI; Izabela STUPKA
- Web page: https://patentgrep.com/patent/US20240181077A1

## CPC

- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61K 9/5192: {Processes}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 41/0042: {Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6949: {inclusion complexes, e.g. clathrates, cavitates or fullerenes}
- C07K 14/195: from bacteria
- A61K 2039/6031: {Proteins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides an artificial TRAP-cage comprising a selected number of TRAP rings and encapsulated therein a guest cargo.

## Claims

### Claim 1

An artificial TRAP-cage comprising a selected number of TRAP rings and encapsulated therein at least one guest cargo.

### Claim 2 (depends on 1)

The cage according to claim 1, wherein the guest cargo is selected from the group comprising a protein, an enzyme, an antigen, an antibody. a protein macromolecule a lipid, a peptide, a nucleic acid, a small molecular cargo, a peptide nucleic acid, a carbon- based structure, a metal, a toxin or a nanoparticle.

### Claim 3 (depends on 2)

The cage according to claim 2, wherein the nucleic acid is selected from the group comprising DNA, RNA, mRNA, siRNA, tRNA and micro-RNA.

### Claim 4 (depends on 2)

The cage according to claim 2, wherein the enzyme is an enzyme associated with an over-expression in a metabolic disorder or disease or an underexpression in a metabolic disorder or disease.

### Claim 5 (depends on 4)

The cage according to claim 4, wherein the enzyme is selected from the group comprising hydrogenase, dehydrogenase, lipase, lyase, ligase, protease, transferase, reductase, recombinase and nuclease acid modification enzyme.

### Claim 6 (depends on 2)

The cage according to claim 2, wherein the therapeutic agent is selected from the group comprising a cancer therapeutic, an anti-infection therapeutic, a vascular disease therapeutic, an immune therapeutic, senolytic and a neurological therapeutic.

### Claim 7 (depends on 2)

The cage according to claim 2 wherein the metal is selected from the group comprising iron, zinc, platinum, copper, sodium, cadmium, lanthanide, gadolinium, technetium, calcium, potassium, chromium, magnesium, molybdenum and salts or complexes thereof.

### Claim 8 (depends on 2)

The cage according to claim 2 wherein the toxin is selected from the group comprising a ligand targeted toxin, a protease activated toxin, melittin and a toxin-based suicide gene therapeutic.

### Claim 9

The cage according to any preceding claim, wherein the guest cargo is a protein and preferably the protein is a fluorescent protein, interleukin-2 (IL-2) or Neoleukin-2/15 (NL-2).

### Claim 10 (depends on 2, 3, 4, 5, 6, 7, 8, 9)

The cage according to any preceding claim wherein the cage comprises multiple guest cargos and wherein the guest cargoes are the same or different from one another, and are any combination of the cargos from claims 2 to 9.

### Claim 11

The cage according to any preceding claim, further including at least one external decoration.

### Claim 12 (depends on 11)

The cage according to claim 11, wherein at least one of the external decorations comprises a cell penetrating agent to promote intracellular delivery of the cage containing an internal guest cargo.

### Claim 13 (depends on 12)

The cage according to claim 12, wherein the cell penetrating agent is PTD4.

### Claim 14

The cage according to any preceding claim, wherein the number of TRAP rings in the TRAP-cage is between 6 to 60.

### Claim 15 (depends on 14)

The cage according to claim 14, wherein the number of TRAP rings in the TRAP-cage is 12, 20 or 24, preferably 24.

### Claim 16

The cage according to any preceding claim, wherein the interior surface of the TRAP-cage lumen is supercharged and the TRAP-cage protein comprises a E48Q or a E48K mutation.

### Claim 17

The cage according to any preceding claim, wherein the artificial TRAP-cage protein is modified to comprise any one or more of the following mutations selected from the group comprising, comprising K35C, K35H, R64S, E48Q, E48K, K35C/R64S, K35H/R64S, S33C, S33H, S33C/R64S, S33H/R64S, S33C/K35H S33H/K35H, S33C/K35C, S33H/K35C, K35C/E48Q, K35C/E48K, K35H/E48Q, K35H/E48K, S33C/E48Q, S33C/E48K, S33C/E48Q and S33C/E48K.

### Claim 18

The TRAP-cage according to any preceding claim, wherein opening of the cage is programmable.

### Claim 19 (depends on 18)

The TRAP-cage according to claim 18, wherein the programmable opening of the cage is dependent on selection of a molecular or atomic cross-linker which hold the TRAP-rings in place in the TRAP-cage.

### Claim 20 (depends on 19)

The TRAP-cage according to claim 19, wherein the cross-linker is either (i) a reduction responsive/sensitive linker, whereby the cage opens under reduction conditions; or (ii) a photo-activatable linker whereby the cage opens upon exposure to light.

### Claim 21

Use of the artificial TRAP-cage according to any preceding claim as a delivery vehicle for intracellular delivery of its internal guest cargo.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

Use of the artificial TRAP-cage according to any one of claims 1 to 20 as a vaccine.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

Use of the artificial TRAP-cage according to any one of claims 1 to 20 for the treatment of an illness or disease condition selected from the group comprising cancer, vascular disease, cardiovascular disease, diabetes, infection, auto-immune condition, neurodegenerative disease, cellular senescence disease, arthritis and respiratory disease.

### Claim 24

A method of making an artificial TRAP-cage with an encapsulated guest cargo, the method comprising:
(i) obtaining TRAP ring units by expression of the TRAP ring units in a suitable expression system and purification of the said units from the expression system;
(ii) conjugation of the TRAP ring units via at least one free thiol linkage with a cross-linker;
(iii) modification of the TRAP ring units to provide a suitable interior surface environment for capturing a guest cargo;
(iv) formation of the TRAP-cage by self-assembly to provide a cage lumen wherein the guest cargo is encapsulated; and
(v) purification and isolation of the TRAP-cages encapsulating the guest cargo.

### Claim 25 (depends on 24)

The method of claim 24 wherein the modification of step (iii) is selected from the group comprising:
(i) super charging the interior surface of the TRAP-cage lumen;
(ii) genetic fusion of the guest cargo to an interior surface of the TRAP-cage lumen;
(iii) SpyCatcher/SpyTag conjugation of the guest cargo to an interior surface of the TRAP-cage lumen; and
(iv) via covalent bond formation in both chemical and enzymatic methods.

### Claim 26 (depends on 24, 25)

The method of claim 24 or 25 wherein step (ii) first comprises conjugation of the TRAP ring units via at least one metal cross-linker, preferably an atomic metal cross-linker, then replacing the metal cross-linker with a molecular cross-linker.

### Claim 27 (depends on 24, 25, 26)

The method according to any one of claims 24 to 26, wherein the super charging of step (i) of the interior surface provides either a net positive or net negative charge on the interior surface of the cage lumen.

### Claim 28 (depends on 24, 25, 26, 27)

The method according to any one of claims 24 to 27, wherein the artificial TRAP-cage protein is modified to comprise any one or more of the following mutations selected from the group comprising, comprising K35C, K35H, R64S, E48Q, E48K, K35C/R64S, K35H/R64S, S33C, S33H, S33C/R64S, S33H/R64S, S33C/K35H S33H/K35H, S33C/K35C, S33H/K35C, K35C/E48Q, K35C/E48K, K35H/E48Q, K35H/E48K, S33C/E48Q, S33C/E48K, S33C/E48Q and S33C/E48K.

### Claim 29 (depends on 28)

The method according to any of claim 28 wherein the cage formation step of part (iii) for TRAPK35C E48Q is performed in sodium bicarbonate buffer at pH 9-11.

### Claim 30 (depends on 28)

The method according to any of claim 28 wherein the cage formation step of part (iii) for TRAPK35C E48k is performed in sodium bicarbonate buffer at pH 10-10.5.

### Claim 31 (depends on 24, 25, 26, 27, 28, 29, 30)

The method according to any one of claims 24 to 30, wherein the guest cargo can be loaded either pre or post assembly of the TRAP-cage.

### Claim 32 (depends on 24, 25, 26, 27, 28, 29, 30, 31)

The method according to any one of claims 24 to 31, wherein the genetic fusion of the guest cargo to an interior surface of the TRAP-cage lumen of step (ii) is via N-terminus fusion of the guest cargo to an N-terminus of TRAPK35C which faces into the interior surface of the lumen.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the SpyCatcher/SpyTag conjugation of the guest cargo to an interior surface of the TRAP-cage lumen of step (iii) wherein the SpyCatcher is introduced in a loop region of TRAP rings between residues 47 and 48, which faces to the interior when assembled into TRAP-cages and the guest cargo contains a SpyTag.

### Claim 34 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method according to any one of claims 24 to 33, wherein enzymatic modification is via peptide ligase selected from the group comprising sortases, asparaginyl endoproteases, trypsin related enzymes and subtilisin-derived variants and covalent chemical bond formation may include strain promoted alkyne-azide cycloaddition and pseudopeptide bonds.

### Claim 35 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A TRAP cage produced by method of any one of claims 24 to 34.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

Use of the cage according to any one of claims 1 to 20 as a medicament.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method of treating a patient, comprising administering a cage according to any one of claims 1 to 20 to said patient.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The cage according to any one of claims 1 to 20 for use in treating a disease in a patient or as a vaccine.

### Claim 39

An artificial TRAP-cage protein modified to comprise any one or more of the following mutations selected from the group comprising K35C, K35H, R64S, E48Q, E48K, K35C/R64S, K35H/R64S, S33C, S33H, S33C/R64S, S33H/R64S, S33C/K35H S33H/K35H, S33C/K35C, S33H/K35C, K35C/E48Q, K35C/E48K, K35H/E48Q, K35H/E48K, S33C/E48Q, S33C/E48K, S33C/E48Q and S33C/E48K.

### Claim 40

A method of treatment of an individual in need of therapy suffering from a condition selected from the group comprising cancer, vascular disease, cardiovascular disease, diabetes, infection, auto-immune condition, neurodegenerative and neurological disease, cellular senescence disease, arthritis and respiratory disease, the method comprising administering a therapeutically effective amount of an artificial TRAP-cage bearing one or more internal guest cargo selected from the group comprising a nucleic acid, an enzyme, a therapeutic agent, a small molecule, organic or inorganic nanoparticles, a peptide, a metal, an antigen, an antibody and toxin and fragments thereof of all the foregoing that are of therapeutic value.

### Claim 41

A method of vaccinating an individual in need of vaccination from a condition selected from the group comprising cancer, vascular disease, cardiovascular disease, diabetes, infection, auto-immune condition, neurodegenerative and neurological disease, cellular senescence disease, arthritis and respiratory disease, the method comprising administering a therapeutically effective amount of an artificial TRAP-cage bearing one or more internal guest cargo selected from the group comprising a nucleic acid, an enzyme, a therapeutic agent, a small molecule, organic or inorganic nanoparticles, a peptide, a metal, an antigen, an antibody and toxin and fragments thereof of all the foregoing that are of therapeutic value

### Claim 42 (depends on 40, 41)

The methods of either claim 40 or 41 wherein the TRAP-cage therapeutic is administered via intranasal inhalation or injection.
